Clinical Trial Update: A Long-Term Study of Navenibart in Participants With Hereditary Angioedema [Phase 3]

View source ↗

Summary

A long-term Phase 3 study evaluating Navenibart in participants with hereditary angioedema is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Navenibart

Snippet

Sponsor: Astria Therapeutics, Inc. | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: ENROLLING_BY_INVITATION